SuperworthRenovoRx RNXT
- Market cap
- $58.2M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 29.5×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $2M
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- −20.5%
RenovoRx trades at 29.5× sales. Revenue was $2M over the last twelve months.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | $197K | $422K | $266K | $238K | $563K+186% | $909K+115% | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | $94K | $152K | $53K | $28K | $84K−11% | $143K−6% |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | $103K | $270K | $213K | $210K | $479K+365% | $766K+184% |
| R&D | $1.6M+93% | $775K−0% | $1.3M−6% | $1.5M−20% | $1.6M+1% | $1.6M+103% | $1.6M+31% | $1.4M−8% | $1.7M+2% | $1.5M−5% | $1.2M−25% | $1.2M−16% |
| SG&A | $1.4M+3% | $1M−28% | $1.2M−37% | $1.5M+3% | $1.2M−13% | $1.1M+10% | $1.6M+29% | $1.5M+2% | $1.7M+47% | $2.2M+103% | $2.7M+73% | $2.9M+92% |
| −$3M+38% | −$1.8M−18% | −$2.5M−24% | −$3M−10% | −$2.8M−5% | −$2.6M+48% | −$3.1M+26% | −$2.7M−12% | −$3.2M+13% | −$3.5M+34% | −$3.5M+12% | −$3.3M+25% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Net income | −$1.4M−34% | −$3.2M+50% | −$1.1M−67% | −$2.4M+3% | −$2.5M+74% | n/a | −$2.4M+125% | −$2.9M+21% | −$2.9M+18% | n/a | n/a | n/a |
| −$0.13−46% | −$0.30+25% | −$0.07−81% | −$0.10−55% | −$0.10−23% | n/a | −$0.08+14% | −$0.08−20% | −$0.08−20% | n/a | −$0.09+13% | −$0.06−25% | |
| 10.7M+18% | 10.7M+18% | 14.9M+64% | 24M+126% | 24.9M+133% | 25.1M+135% | 31.4M+110% | 36.6M+52% | 36.6M+47% | 36.6M+46% | 38M+21% | 47.3M+29% |
EPS, diluted: 4 periods, Q4 FY20 to Q4 FY23: quarter's net income to common over its shares, to the cent.
Diluted shares: 4 periods, Q4 FY20 to Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY24 and Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest RenovoRx's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| RNXTRenovoRx | $58.2M | n/m | n/a | 29.5× | n/m | n/m | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| TCMDTactile Systems Technology | $535.5M | 21.9× | 62.9× | 1.5× | +17% | 7.1% | |
| MDXGMimedx | $569.9M | 97.8× | 21.1× | 1.6× | −2% | 1.8% | |
| Peer median | $236.3M | 21.9× | 20.9× | 1.6× | +5% | 7.1% |
More on RenovoRx
Each number over time
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .